Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.46 |
| ▸ | PPARA | Q07869 | 10/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016024 | 1.00 | PPARG (0.46) | PPARGPPARACYP2C9MEN1ALDH1A1 | |
| SCHEMBL5016025 | 1.00 | PPARG (0.46) | PPARGPPARACYP2C9MEN1ALDH1A1 | |
| SCHEMBL5015813 | 0.93 | MAPT (0.44) | PPARGPPARACYP2C9MEN1ALDH1A1 | |
| SCHEMBL5015812 | 0.93 | MAPT (0.44) | PPARGPPARACYP2C9MEN1ALDH1A1 | |
| SCHEMBL5015808 | 0.93 | MAPT (0.44) | PPARGPPARACYP2C9MEN1ALDH1A1 | |
| SCHEMBL5017744 | 0.92 | PPARG (0.45) | PPARGPPARACYP2C9MEN1ALDH1A1 | |
| SCHEMBL5017741 | 0.92 | PPARG (0.45) | PPARGPPARACYP2C9MEN1ALDH1A1 | |
| SCHEMBL5017743 | 0.92 | PPARG (0.45) | PPARGPPARACYP2C9MEN1ALDH1A1 | |
| SCHEMBL5017946 | 0.88 | FFAR1 (0.54) | PPARGPPARAMAPTFFAR1KDR | |
| SCHEMBL5017941 | 0.88 | FFAR1 (0.54) | PPARGPPARAMAPTFFAR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551814-B1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7348349-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20050267180-A1 | Novel oxazole derivatives | BINGGELI ALFRED | 2005-12-01 | — | — | US | disclosed |
| US-6969725-B2 | Oxazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1551814-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267180-A1 | Novel oxazole derivatives | NR1H3, NR1H2, PPARD | PPARG 7/4885PPARA 6/4885CYP2C9 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.